PMID- 25189461
OWN - NLM
STAT- MEDLINE
DCOM- 20160515
LR  - 20220318
IS  - 1559-0305 (Electronic)
IS  - 1073-6085 (Linking)
VI  - 56
IP  - 12
DP  - 2014 Dec
TI  - Comparative evaluation of cardiac markers in differentiated cells from menstrual 
      blood and bone marrow-derived stem cells in vitro.
PG  - 1151-62
LID - 10.1007/s12033-014-9795-4 [doi]
AB  - In recent years, menstrual blood-derived stem cells (MenSCs) have been introduced 
      as easily accessible and refreshing stem cell source without ethical 
      considerations in the field of regenerative medicine. The aim of this study was 
      to investigate in vitro cardiac differentiation capacity of MenSCs compared to 
      bone marrow-derived stem cells (BMSCs) under two protocols using 
      5-aza-2'-deoxycytidine (5-aza) and basic fibroblast growth factor (bFGF). Our 
      data revealed that differentiated MenSCs and BMSCs acquired some features of 
      cardiomyocytes; however, degree of differentiation was dependent on the protocol. 
      In a similar manner with BMSCs, differentiated MenSCs showed upper levels of 
      mRNA/protein of late-stage cardiac markers under 5-aza stimulation and continuous 
      treatment with bFGF (protocol 2) compared to those induced by 5-aza alone 
      (protocol 1) evidencing the key role of bFGF in cardiac development of stem 
      cells. Compared to corresponding undifferentiated cells differentiated MenSCs 
      under protocol 2 showed remarkable expression of connexin-43 and TNNT2 at both 
      gene and protein levels, whereas developed BMSCs under the same condition only 
      expressed connextin-43 at the higher level. Superiority of protocol 2 over 
      protocol 1 was confirmed by assessment of LDH and cTnI production by 
      differentiated cells. Based on the accumulative data, our study provided 
      convincing evidence that MenSCs have relatively higher capability to be 
      differentiated toward cardiomyocyte compared with BMSCs. Furthermore, usage of 
      bFGF and 5-aza to induce in vitro cardiac differentiation of MenSCs is highly 
      recommended.
FAU - Rahimi, Maryam
AU  - Rahimi M
AD  - Department of Animal Biology, Faculty of Biological Sciences, Kharazmi 
      University, Tehran, Iran.
FAU - Zarnani, Amir-Hassan
AU  - Zarnani AH
FAU - Mohseni-Kouchesfehani, Homa
AU  - Mohseni-Kouchesfehani H
FAU - Soltanghoraei, Haleh
AU  - Soltanghoraei H
FAU - Akhondi, Mohammad-Mehdi
AU  - Akhondi MM
FAU - Kazemnejad, Somaieh
AU  - Kazemnejad S
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Switzerland
TA  - Mol Biotechnol
JT  - Molecular biotechnology
JID - 9423533
RN  - 0 (Biomarkers)
RN  - 103107-01-3 (Fibroblast Growth Factor 2)
RN  - 776B62CQ27 (Decitabine)
RN  - M801H13NRU (Azacitidine)
SB  - IM
MH  - Adult
MH  - Azacitidine/analogs & derivatives/pharmacology
MH  - Biomarkers/*metabolism
MH  - Blood Cells/*cytology/metabolism
MH  - Bone Marrow Cells/*cytology/metabolism
MH  - Cell Differentiation/drug effects
MH  - Decitabine
MH  - Female
MH  - Fibroblast Growth Factor 2/pharmacology
MH  - Humans
MH  - Menstruation/*blood/metabolism
MH  - Myocytes, Cardiac/*metabolism
MH  - Stem Cells/*cytology/metabolism
MH  - Young Adult
EDAT- 2014/09/06 06:00
MHDA- 2016/05/18 06:00
CRDT- 2014/09/06 06:00
PHST- 2014/09/06 06:00 [entrez]
PHST- 2014/09/06 06:00 [pubmed]
PHST- 2016/05/18 06:00 [medline]
AID - 10.1007/s12033-014-9795-4 [doi]
PST - ppublish
SO  - Mol Biotechnol. 2014 Dec;56(12):1151-62. doi: 10.1007/s12033-014-9795-4.